Search
Searching Content indexed under Life Sciences, Biotechnology & Nanotechnology by Stikeman Elliott LLP ordered by Published Date Descending.
Links to Result pages
 
1  
 
Title
Country
Organisation
Author
Date
1
Operationalizing Health Canada's Authority To Assess Medical Devices Post-Approval: The Latest On The Regulatory Consultation Process
In 2014, amendments to the Food and Drugs Act gave the federal Minister of Health authority with respect to the safety of drugs, medical devices and other therapeutic devices that are already
Canada
9 Jul 2019
2
Mise en œuvre du pouvoir qu'a Santé Canada d'évaluer les instruments médicaux après leur approbation : Le point sur le processus de consultation réglementaire
En 2014, des modifications apportées à la Loi sur les aliments et drogues ont conféré au ministre fédéral de la Santé le pouvoir de régir la sûreté des médicaments, des instruments médicaux et des autres appareils thérapeutiques qui sont déjà sur le marché.
Canada
5 Jul 2019
3
Canada
16 Nov 2018
4
As Third-Party Class Action Funders Make Their Mark In Canada, An Ontario Court Establishes Some Ground Rules
Over the past few years, third-party litigation funding – including funding by major international litigation funders – has become increasingly common in class actions litigation in Canada.
Canada
21 Aug 2018
5
B.C. Court Dismisses Proposed Class Action Against Generic Manufacturers Of Fentanyl Patch
Justice Bracken of the British Columbia Supreme Court dismissed a proposed class action against two generic manufacturers of transdermal fentanyl patches.
Canada
17 Jul 2014
6
Federal Court Prevents Minister Of Health From Allowing Sale Of Generic Version Of Immunosuppressive Drug MMF
In an application pursuant to the Patented Medicines (Notice of Compliance) Regulations, Hoffman-La Roche sought an order preventing the Minister of Health from issuing a notice of compliance to Apotex for the drug mycophenolate mofetil (MMF).
Canada
5 Sep 2011
7
Federal Court Of Appeal Confirms That Eli Lilly's Patent To Atomoxetine Is Invalid For Lack Of Utility
The Federal Court of Appeal recently released its decision in Eli Lilly and Company v Teva Canada Ltd, confirming the trial court’s finding.
Canada
23 Aug 2011
8
Supreme Court Of Canada Finds Patented Medicine Prices Review Board Has Jurisdiction Over Price Of Thalomid In Canada
The Supreme Court of Canada released a decision on January 20, 2011 in Celgene Corp. v. Canada (Attorney General), 2011 SCC 1 that may have a chilling effect on the availability of medicines under Health Canada’s Special Access Program (SAP).
Canada
1 Feb 2011
9
Federal Court Of Appeal Upholds The Data Protection Regulations And Its Guaranteed Eight-Year Period Of Market Exclusivity For "Innovative Drugs"
The Federal Court of Appeal has upheld the validity of section 30(3) of the Food and Drugs Act and section C.08.004.1 of the Food and Drug Regulations (known as the Data Protection Regulations) in its decision in Apotex Inc. v. The Minister of Health, 2010 FCA 334.
Canada
1 Feb 2011
10
Dedication of Merck Patent Insufficient to Defeat Allegation of Double Patenting
A recent decision of the Federal Court expounded on the harm that can occur if two patents issue for the same invention.
Canada
5 Dec 2010
11
Apotex Succeeds In Getting A NOC Despite Itself
A recent Federal Court decision highlighted the differences in prohibition proceedings under the Patented Medicines (Notice of Compliance) Regulations (the NOC Regulations) and impeachment actions under the Patent Act.
Canada
5 Dec 2010
12
Federal Court Of Appeal Refuses A Patent To A Compound Already The Subject Matter Of Product-By-Process Patent
On October 20, the Federal Court of Appeal put an end to the disparity in the jurisprudence surrounding whether a patentee could obtain a patent to a medicine subsequent to obtaining a patent to a process for producing the medicine by dismissing Bayer’s appeal in the case of Bayer Schering Pharma Aktiengesellschaft v. The Attorney General of Canada.
Canada
5 Dec 2010
13
Eli Lilly Patent for Atomoxetine for use in Treating ADHD Invalid for Lack of Utility
Novopharm Limited (now known as Teva Canada Limited but hereafter referred to as Novopharm) sought a declaration under s. 60(1) of the Patent Act, R.S.C. 1985, c. P-4 that Eli Lilly and Company’s (Lilly’s) Canadian Patent No. 2,209,735 (the ‘735 Patent) was invalid and void. The ‘735 Patent claimed the use of the medicine atomoxetine for treating attention deficit hyperactivity disorder (ADHD) in three of its manifestations among all age groups (children, adolescents and adults). The ‘735 Patent
Canada
25 Oct 2010
14
Court Finds AstraZeneca Patent To Esomeprazole (NEXIUM) Invalid For Lack Of Sound Prediction And Obviousness
This was an application brought by AstraZeneca under the provisions of the Patented Medicines (Notice of Compliance) Regulations for an order prohibiting the Minister of Health from issuing a notice of compliance to Apotex for 20 and 40 mg esomeprazole magnesium tablets until after the expiry of Canadian Patent No. 2,139,653 (the ‘653 patent).
Canada
13 Sep 2010
15
Court Of Appeal Rejects Pfizer's Alleged Factual And Legal Errors And Upholds Invalidity Of Pfizer's Patent To NORVASC
Pfizer appealed from a decision of the Federal Court declaring Pfizer’s Canadian Patent No. 1,321,393 ( ‘393 Patent) relating to the medicine amlodipine besylate (NORVASC) invalid for obviousness.
Canada
13 Sep 2010
16
Federal Court Confirms Requirement of Patent Specificity for Listing Patents on the Patent Register
Purdue Pharma sought judicial review of a decision of the Office of Patented Medicines and Liaison (OPML) in which the OPML determined that one of Purdue’s patents (the 738 Patent) was not eligible for listing on the Patent Register maintained in accordance with the Patented Medicines (Notice of Compliance) Regulations (Regulations) in respect of the drug TARGIN.
Canada
28 Jul 2010
17
Commissioner Signals Interest in Innovation Issues
The Competition Bureau has commissioned a review paper of several major issues arising at the interface between competition law and intellectual property law.
Canada
2 Jul 2007
18
Competition Bureau To Investigate Issues At Interface Of Competition Law And Intellectual Property
Together with Industry Canada and the Canadian Intellectual Property Office, the Canadian Competition Bureau has commissioned a review paper of several major issues arising at the interface between competition law and intellectual property law.
Canada
 
16 Jul 2006
Links to Result pages
 
1